The phase I,II clinical study of cancer vaccine for intractable malignant tumor expressing MAGE-A4-antige
Phase 1
- Conditions
- Intractable malignant tumors expressing MAGE-A4 antigen
- Registration Number
- JPRN-UMIN000001999
- Lead Sponsor
- Department of Surgical Oncology, Hokkaido University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 18
Inclusion Criteria
Not provided
Exclusion Criteria
HIV positive, autoimmune diseases,pregnancy,breast feeding
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method the adverse events and the ability to induce antigen specific immune responses
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie MAGE-A4 antigen expression in intractable malignant tumors?
How does the MAGE-A4 cancer vaccine compare to standard-of-care treatments for refractory tumors?
Which biomarkers are associated with response to MAGE-A4-targeted cancer vaccines in clinical trials?
What adverse events are reported in MAGE-A4 vaccine trials and how are they managed?
Are there combination therapies involving MAGE-A4 vaccines and other immunotherapics for malignant tumors?